Avacopan Drug Asset Due Diligence Report 2026

This Avacopan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Avacopan can convert its Small molecule drug profile and C5AR1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Avacopan (query alias: avacopan)
Modality / target	Small molecule drug; C5AR1; C5AR1 antagonists
Highest global status	Approved
Originator	ChemoCentryx, Inc., Vifor Fresenius Medical Care Renal Pharma France
Active developers	Vifor Fresenius Medical Care Renal Pharma France, Hangzhou Tigermed Consulting Co., Ltd., ChemoCentryx, Inc.

The MCP disease footprint includes Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatosis With Polyangiitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07373262	Phase 3	Not yet recruiting	130	Improvement in the kidney function
NCT07176546	Phase 2/3	Not yet recruiting	30	Proportion of patients in ENT remission without relapse
NCT07556484	Phase 1	Recruiting	6	Change in Avacopan blood level over time

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

CARDIOVASCULAR OUTCOMES IN PHASE 4 TRIALS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN INFLAMMATORY ARTHRITIS AND CONNECTIVE TISSUE DISEASES

Phase 4; n=4; evaluation: Negative. Reported fields: Hypertension = 25.0 % ; Hypertension = 13.0 %

ONE YEAR REAL-WORLD EFFECTIVENESS AND SAFETY WITH AVACOPAN IN GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS IN TWO LARGE HEALTHCARE SYSTEMS

Not Applicable; n=159; evaluation: Positive. Reported fields: BVAS(0) = 85.8 %

CLINICAL OUTCOMES BY GLUCOCORTICOID DURATION IN INDIVIDUALS WITH GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS TREATED WITH AVACOPAN IN A REAL-WORLD SETTING IN TWO LARGE HEALTHCARE SYSTEMS

Not Applicable; n=148; evaluation: Positive. Reported fields: ANCA(negative at month 6 among patients who were ANCA-positive at baseline) = 46.6 % ; ANCA(negative at month 6 among patients who were ANCA-positive at baseline) = 54.1 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Avacopan addresses Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatosis With Polyangiitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-07-03	安进获得首创新药TAVNEOS®(阿伐可泮）的商业化权益，加速服务更多中国患者	Approved	Financial terms not disclosed
2022-08-04	Amgen To Acquire Chemocentryx For $4 Billion In Cash	Approved	US$3,700.0M stated total
2017-06-09	Kissei Pharmaceutical and Vifor Fresenius Medical Care Renal Pharma have signed an exclusive license agreement	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Avacopan formulations”. The milestone feed surfaced a patent-application signal described as “Processes for preparation of avacopan and intermediates thereof”. The milestone feed surfaced a patent-application signal described as “C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO